Open Essex

Pet Therapeutic Antibody R&D

Pet Therapeutic Antibody R&D

We offer a comprehensive platform for veterinary antibody development, from initial target validation in canine and feline systems to lead candidate selection. Our expertise covers de novo antibody discovery, species-specific engineering (including "caninization" and "felinization") to improve safety and efficacy, and a full suite of in vitro functional assays to characterize your therapeutic antibody's mechanism of action.

Pet Cell-based Therapy R&D
Our team provides critical support for innovators in veterinary regenerative medicine, focusing on therapies like mesenchymal stem cells (MSCs). We manage the entire pre-clinical workflow, including the isolation, expansion, and thorough characterization of veterinary cell populations, and develop custom-designed potency assays to ensure product consistency and biological activity for conditions like osteoarthritis or IBD.

Pet Health In Vitro Model Customization
Reliable translational data begins with predictive in vitro models. We design and validate biologically relevant assays using canine and feline primary cells, stable cell lines, and advanced 3D culture or organoid systems. These customized models mimic the in vivo microenvironment, enabling robust screening and mechanism-of-action studies for oncology, inflammatory, or metabolic diseases.

Pet Health Animal Model Customization
Our in vivo pharmacology services provide the critical data needed to advance your therapeutic. We possess deep expertise in developing, validating, and executing studies in both rodent and target companion animal models (dogs and cats). We conduct efficacy, safety/tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) studies with the highest ethical standards, delivering the decision-driving data you need for regulatory submissions.